In younger individuals with obesity or diabetes, intensify lifestyle interventions and, where appropriate, utilize GLP-1 receptor agonists and SGLT2 inhibitors, which have demonstrated cardiovascular benefits in recent trials including younger subgroups [103]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.